Medicines planning
48 results
Applied filters
The licence and supporting evidence for omalizumab biosimilar
21 January 2026One omalizumab biosimilar is currently available: Omlyco. Learn about the licensed indications, available preparations, supporting evidence and key differences.
Preparing to use omalizumab biosimilar
20 January 2026One omalizumab biosimilar (Omlyclo) is available and other biosimilars are in development. We offer general information and implementation advice.
The licence and supporting evidence for denosumab 60mg biosimilars
16 January 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use denosumab 60mg biosimilar
16 January 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
Preparing to use denosumab 120mg biosimilar
16 January 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.
Annual medicines planning publication, Prescribing Outlook
12 January 2026Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
New Medicines News
9 January 2026New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
Preparing to use golimumab biosimilar
9 January 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
New Product Evaluations
22 December 2025A list of new product evaluations that are freely available to NHS staff.